FRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI), a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, today reported its financial results as of and for the three and nine months ended September 30, 2011. For the three months ended September 30, 2011, the Company reported a net loss of $7.1 million, or $0.25 per diluted share, compared to a net loss of $7.8 million, or $0.29 per diluted share, for the same period in 2010. For the nine months ended September 30, 2011, the Company reported a net loss of $23.3 million, or $0.83 per diluted share, compared to a net loss of $23.9 million, or $1.02 per diluted share, for the same period in 2010. The Company ended the quarter with $66.8 million of cash and cash equivalents and investments.
